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Key Points
• Early peripheral blast
clearance assessed by
flow cytometry was
a powerful independent
predictive factor of
treatment outcome.
•Clearance rate corre-
lated significantly with
induction intensity,
supporting the use of
this assay in treatment
modulation studies.
Although genetics is a relevant risk factor in acute myeloid leukemia (AML), it can be
minimally informative and/or not readily available for the early identification of patients at
risk for treatment failure. In a randomized trial comparing standard vs high-dose induction
(ClinicalTrials.gov #NCT00495287), we studied early peripheral blast cell clearance (PBC) as
a rapid predictive assay of chemotherapy response to determine whether it correlates with
the achievement of complete remission (CR), as well as postremission outcome, according to
induction intensity. Individual leukemia-associated immunophenotypes (LAIPs) identified
pretherapy by flow cytometry were validated and quantified centrally after 3 days of
treatment, expressing PBC on a logarithmic scale as the ratio of absolute LAIP1 cells on day 1
and day 4. Of 178 patients, 151 (84.8%) were evaluable. Patients in CR exhibited significantly
higher median PBC (2.3 log) compared with chemoresistant patients (1.0 log; P , .0001).
PBC , 1.0 predicted the worst outcome (CR, 28%). With 1.5 log established as the most
accurate cutoff predicting CR, 87.5% of patients with PBC .1.5 (PBChigh, n 5 96) and 43.6%
of patients with PBC #1.5 (PBClow, n 5 55) achieved CR after single-course induction
(P , .0001). CR and PBChigh rates were increased in patients randomized to the high-dose
induction arm (P 5 .04) and correlated strongly with genetic/cytogenetic risk. In
multivariate analysis, PBC retained significant predictive power for CR, relapse risk,
and survival. Thus, PBC analysis can provide a very early prediction of outcome, correlates
with treatment intensity and disease subset, and may support studies of customized
AML therapy.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disease with large variations in prognosis. Among
prognostic factors, karyotype and molecular genetics are the most relevant and represent the framework
of the European LeukemiaNet (ELN) risk stratification system.1,2 Large clinical studies have established
the adequacy of this classification, which provides a general prediction of a priori AML chemosensitivity
and correlates with the achievement of complete remission (CR) and long-term survival.3,4 Nevertheless,
the response to induction chemotherapy remains a powerful prognostic parameter. Within responsive
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patients who enter CR, minimal residual disease (MRD) is emerg-
ing as a strong adjunctive tool to refine the initial genetic risk
category.5-7 Typically, MRD is evaluated after $1 chemotherapy
course. In some studies, an early evaluation of bone marrow (BM)
status 7 days after completion of induction chemotherapy has been
shown to predict outcome, pointing out the importance of the early
disappearance of AML blasts.8
To assess an earlier prognostic parameter, several studies have
evaluated the kinetics of AML cell reduction in peripheral blood (PB)
samples after a few days of induction chemotherapy. Studies based
on a morphological analysis of blood smears have been informative
for separating patients with different induction outcomes and
prognoses.9,10 The French group Groupe Ouest Est Leucemies
Aigues Myeloblastiques studied decreases in blast cells by
multiparameter flow cytometry (MFC), showing a clear correlation
with outcome.11 In that study, blast cell decrease was expressed by
a time-to-clearance modality between baseline and the day that
90% of the initial blast cell load had disappeared.11 Another MFC
study from China confirmed that patients with quicker blast
reduction had greater CR and lower relapse rates.12
In a pilot study using daily MFC analysis of peripheral blast
clearance (PBC), we demonstrated a clear dichotomy between
responsive and refractory patients from day 2 of induction therapy,
establishing day 4 as the most informative PBC time point for
estimating the probability of a response.13,14 Despite the fact that
PBC was a powerful prognostic indicator for CR achievement and
survival in all of these studies, no clinical study has been designed to
assess PBC-related results in a prospective phase 3 trial comparing
different induction chemotherapy regimens. These types of data
would greatly increase the interest in using PBC analysis for PBC-
modulated induction trials because of the potential advantage
offered by rapid customization of chemotherapy intensity in patients
classified as being at high risk for failure. To collect this evidence
and validate the findings of the pilot single-center study in a larger
multicenter setting with centralized analysis, the PBC study was
embedded in the Northern Italy Leukemia Group (NILG) AML 02/06
phase 3 trial,15 in which adult AML patients were randomly allocated
to standard- or high-dose CR induction chemotherapy. The aim of the
PBC study was to compare PBC responses and related therapeutic
outcomes in the 2 randomization cohorts and across different AML
risk subsets.
Patients and methods
Patients and AML diagnosis
Eligible patients had a diagnosis of untreated AML, according to
World Health Organization criteria.16 AML subtypes were defined
by cytogenetics, histopathology, and molecular genetics.17 For the
NPM1 mutation, core marrow biopsies were studied at the Institute
of Hematology, Perugia University (Italy).18 For molecular biology
(MLL and core binding factor [CBF] gene rearrangements, FLT3
internal tandem duplication, and CEBPA mutations), fresh blood
and marrow samples and frozen DNA/RNA samples were studied at
the Hematology Unit, Bergamo Hospital (Italy).19-21
Treatment protocol
TheNILGAML 02/06 trial (ClinicalTrials.gov Identifier: NCT00495287)
included randomization between a standard CR induction arm with
12 mg/m2 per day of idarubicin IV on days 1 through 3, 100 mg/m2
per day of etoposide IV on days 1 through 5, and 100 mg/m2 twice-
daily cytarabine IV over 1 hour on days 1 through 7 (ICE) vs a high-
dose sequential (HDS) arm with 2000 mg/m2 twice-daily cytarabine
IV over 2 hours on days 1, 2, 8, and 9 and 18 mg/m2 per day of
idarubicin IV on days 3 and 10. Preinduction hydroxyurea was
allowed in patients with blood counts .50 3 109/L. Other
treatment details, including consolidation therapy, risk-oriented
allotransplantation strategy, and risk definition criteria, were published
previously.15
PBC study
The PBC project was approved as a secondary trial objective with
a study amendment issued in April of 2009 by the Ethical
Committee of the coordinating institution (Department of Hematol-
ogy, Florence University Hospital, Florence, Italy) and other
participating centers. Written informed consent was obtained from
trial patients in accordance with the Declaration of Helsinki. MFC
study files reporting individual LAIP profiles were acquired locally
according to predefined standard operative procedures. LAIPs
were defined by antigen expression on blast cells from fresh
diagnostic BM samples. Standard MFC methodology for LAIP
definition and detection and the PBC study is detailed in
supplemental Files S1 and S2.1. Four LAIP types were considered:
cross-lineage antigen expression, asynchronous antigen expres-
sion, lack of antigen expression, and antigen overexpression
(supplemental File S1).6,22,23 To ensure optimal sensitivity, inclusion
in the PBC study required the presence of $100 circulating LAIP1
cells per microliter at diagnosis. Case-specific LAIP1 cells were
enumerated on EDTA-anticoagulated samples of PB collected
before chemotherapy on days 1 and 4 of the first induction course.
Based on previous studies, day 4 was chosen as the earliest
possible informative PBC time point.14 MFC files, blinded with
regard to clinical and biological features, were sent electronically to
the coordinating center for review and data analysis. The study was
performed using a BD FACSCanto II flow cytometer equipped with
BD FACSDiva Software (both from BD Biosciences, San Jose, CA)
for data acquisition. The files were analyzed using Infinicyt software
(Cytognos, Salamanca, Spain), and PBC data were entered into
electronic case report forms. PBC was expressed as the ratio
between the absolute LAIP1 cell count pretherapy on day 1 and
pretherapy on day 4 converted to a logarithmic (base 10) scale
(Figure 1A).
Definitions
The definitions of CR, nonresponsive (NR) disease, early induction
death (ED), recurrence, disease-free survival (DFS), event-free
survival (EFS), cumulative incidence of relapse (CIR), and overall
survival (OS) were based on standard criteria,24 as reported in the
treatment protocol (supplemental File S1). For risk definition,
patients were stratified according to the original NILG study design
and the ELN 2010 system in post hoc analysis.1 In the NILG risk
classification, the standard-risk (SR) group included patients with
CBF1 AML and those with normal or intermediate-risk cytogenet-
ics/genetics, without any of the following additional risk factors:
diagnosis of minimally differentiated AML, erythroleukemia, mega-
karyoblastic leukemia, granulocytic sarcoma, or central nervous
system leukemia; prior myelodysplastic syndrome (MDS) or
myeloproliferative neoplasm (MPN); prior malignancy treated with
radiotherapy/antineoplastic drugs; white blood cell (WBC) count
.50 3 109/L; or FLT3 mutations. All other patients were included
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in the high-risk (HR) category. The definitions of intermediate- and
high-risk cytogenetics are reported in supplemental File S1. Using
the ELN 2010 genetic classification system, patients were
subdivided into good-risk, intermediate-risk 1, intermediate-risk 2,
and adverse-risk groups.1
Statistical analysis
Receiver operating characteristic (ROC) analysis was performed to
assess the PBC threshold that best discriminated CR achievement
after the first induction course. A cutoff that maximized the
Youden’s index was selected as the optimal threshold; in the case
of equal values, the cutoff with better sensitivity was chosen.
Patients who died during first induction were excluded from the
analysis. Pairwise comparisons between patient characteristics
were performed using the Mann-Whitney U test or the Kruskal-
Wallis test for continuous variables and Pearson’s x2 test or
Fisher’s exact test for categorical variables. Survival was estimated
by the Kaplan-Meier method, and long-term outcomes were
compared using the log-rank test. The incidence of relapse and
overall CR were assessed using the cumulative incidence function,
considering death as a competing event. The Cox proportional
hazard model was applied to estimate hazard ratios with 95%
confidence intervals (CIs) for CR rate after 1 or 2 chemotherapy
courses, CIR, DFS (ie, interval from CR to relapse or death), OS (ie,
interval from study entry to death), and EFS (ie, interval from study
entry to death, failure to achieve CR [2 courses], or relapse), in the
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Figure 1. Overall design of PBC study and correlation with response to induction. (A) Design of the study of PBC within NILG AML trial 02/06. The trial provided
a randomization (R) between standard (ICE) and intensified (HDS) induction chemotherapy. Along treatment, on day 1 and day 4, cells bearing a previously identified aberrant
immune-phenotype (LAIP) were quantified by multiparameter flow cytometry, and files were transmitted to the Coordinating Center for central analysis of data and PBC
calculation. (B) Box plots show the distribution of PBC values according to response to first cycle. (C) ROC curve methodology allowed setting 1.5 logs as the best cutoff at
separating patients with significantly different outcomes. For this threshold, the area under the curve (AUC) was 0.792. (D) Time to achievement of CR according to PBC
category (,1.5 log or $1.5 log).
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univariate and multivariate context. Otherwise, logistic regression
was used to estimate odds ratios with 95%CIs for CR achievement
after the first induction course. All P values were 2-sided, and a 5%
significance level was fixed. Statistical analyses were performed
with SAS version 9.4 and R version 3.5.0.
Results
Patients and LAIPs
The NILG AML 02/06 trial recruited 574 patients at 17 centers.
Between April 2007 andMarch 2012, 4 main study sites adhered to
the PBC project, enrolling 178 patients. A comparative analysis
between studied and nonstudied patients ruled out any selection
bias and confirmed a comparable distribution of pretreatment risk
factors (Table 1) and similar outcomes (supplemental File S2.2).
Twenty-seven eligible patients were excluded from the PBC study
because of absent circulating blasts (n5 7, 3.9%), LAIP1 cell count
,100 per microliter (n5 3, 1.7%), or lack of suitable LAIP (n5 17,
9.6%). A total 151 patients (84.8%) exhibited sufficient LAIP1 cells
within each of the 4 predefined LAIP subtypes and were assessable
for the PBC study (supplemental File S2.3). The clinical character-
istics of the 27 excluded patients were also comparable to the
study population, with the exception of a higher leukocyte count
(supplemental File S2.4). No significant difference emerged among
patients in the 2 trial arms (ICE, n 5 82; HDS, n 5 69), with the
exception of a higher median age for patients in the standard arm,
imputable to the exclusion of many patients older than 65 years from
the randomization (Table 1).
PBC study and CR induction
After the start of induction chemotherapy, the median absolute LAIP
count in the entire study population of 151 PBC-evaluable patients
decreased from 4198 per microliter (range, 120-148 859) at
baseline to 41.8 per microliter (0.07-44 802) on day 4, resulting in
a median PBC of 1.9 log (range, 0.30-4.50) after the first 3 days of
chemotherapy. At the time of the evaluation of responses after
induction course 1, 108 patients achieved CR (71.5%), 9
experienced an ED (6.0%), and 34 were declared NR (22.5%).
NR patients exhibited significantly more residual LAIP1 cells on day
4 compared with CR patients and had a markedly lower median
PBC of 1.0 log compared with 2.3 log (P , .001; Table 2;
Figure 1B). PBC strata (,1.0 vs 1-1.5 vs .1.5) predicted a linear
correlation with CR, with a very low CR rate in patients with PBC,
1.0 (28%) (supplemental File S2.5). The best predictive PBC cutoff
for CR, evaluated by ROC methodology and correlating with the
highest area under the curve AUC (0.792), was 1.5 log (Figure 1C;
supplemental File S2.6). Using this cutoff, 96 of the 151 patients
were in a high PBC range (.1.5 log; PBChigh), and 55 were in a low
PBC range (#1.5 log; PBClow). Using these 2 distinct PBC ranges
as possible predictive markers of different therapeutic responses,
we found that 84 of 96 PBChigh patients (87.5%) achieved a CR
with a single chemotherapy course, compared with only 24 of
55 PBClow patients (43.6%, P , .0001). When evaluated after
a second chemotherapy course administered to NR patients
(n 5 20), the CR rate increased to 90% and 62% in PBChigh
(n 5 86/96) and PBClow (n 5 34/55) patients, respectively
(P , .0001), with overall NR rates of 6% and 29%, respectively.
Consequently, the prognostic difference favoring the PBChigh
group was also reflected in the time-to-CR analysis (Figure 1D).
PBC study and CR induction results according to
randomization arm
By the time PBC was assessed, differences in chemotherapy
included a 50% lower cumulative idarubicin dose (18 vs 36 mg/m2),
a lack of etoposide (0 vs 300 mg/m2), and a substantial increase in
cytarabine dose (8000 vs 600 mg/m2) and exposure time (12 hours
vs 6 hours) in the HDS arm compared with the ICE induction arm.
The single-course CR rate was 61% (n5 50/82) with ICE vs 84.1%
(n 5 58/69) with HDS (P 5 .002), with a lower incidence of
resistant AML (30.5% vs 13%; P5 .0106) and comparable ED rate
(8.5% vs 2.9%; P 5 .18). The average therapy-related PBC
response was 1.8 (0.3-4.5) in the ICE arm and 2.0 (range 0.6-4.2) in
the HDS arm (P 5 .0375). After analyzing the results based on
a high or low PBC response, more patients in the HDS arm
exhibited a PBChigh profile compared with patients in the ICE arm
(72.5% vs 56.1%, P5 .04; Table 2). Altogether, the combined end
point of a PBChigh response at day 4, followed by CR after a single
induction course, was achieved in 47.5% (n 5 39/82) and 72.4%
(n 5 45/69) of the patients in the ICE and HDS arms, respectively
(P5 .04). PBC results did not differ significantly among NR patients
in either study arm.
PBC and prognostic analysis
Using univariate analysis, the achievement of CR was significantly
affected by patient age, diagnosis of MDS/MPN-associated or
secondary AML, risk classification (NILG or ELN), type of induction
chemotherapy, and PBC. PBC strata also significantly affected
the 5-year OS, DFS, EFS, and CIR (supplemental File S2.5). In
multivariate analysis, a PBChigh profile was the most powerful
predictive factor for CR after single-course induction (P , .0001),
along with NILG or ELN risk class (Table 3). Considering the total
CR rate after reinduction course 2, PBC and secondary disease
maintained their independence, whereas risk stratification lost its
impact (supplemental File S2.7). Because of the strong statisti-
cal relationship between PBChigh and CR after course 1, we
investigated the role of pretreatment risk factors in predicting
a good PBC response. A PBChigh status correlated significantly
with a good patient performance score (univariate analysis only), the
use of HDS induction chemotherapy, and a more favorable risk
profile defined by NILG or ELN criteria (supplemental File S2.8).
Thus, considering the ELN-defined subgroups, the average PBC
response ranged from 2.32 for favorable risk to 2.06, 1.49, and 1.32
in the intermediate-1, intermediate-2, and adverse cytogenetic/
genetic risk subsets (P , .0001); corresponding CR rates were
91%, 69%, 61%, and 46%, respectively. CR patients consistently
expressed higher PBC values in each of the 4 risk categories
(Figure 2). The proportion of patients with a PBChigh profile varied
across the 4 risk subsets: 77% (n 5 43/56), 57% (n 5 20/35),
33% (n 5 6/18), and 29% (n 5 10/35) in the favorable-,
intermediate-1, intermediate-2, and adverse-risk subsets, respec-
tively (P , .0001). In contrast, NR rates varied from 9% to 54%
(P , .0001), almost invariably in association with PBClow results.
PBC and survival estimates
A secondary analysis was performed to assess whether PBC
results affected the risk of relapse and survival parameters. PBChigh
patients experienced significantly better long-term outcomes than
did PBClow patients, as indicated by comparative OS and EFS
estimates (Figure 3). The postremission impact of a PBChigh or
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Table 1. Patient characteristics
Trial patients (N 5 572)
PBC study patients
P*All (N 5 151) ICE arm, n 5 82 (54.3 %) HDS arm, n 5 69 (45.7%)
Age, median (range), y 52 (16-73) 53 (20-73) 59.5 (28-73) 47 (20-72) ,.0001
Males, n (%) 301 (52.6) 78 (51.7) 44 (53.66) 34 (49.28) .5913
ECOG performance score, n (%) .6338
0 292 (51.1) 77 (51.0) 39 (47.56) 38 (55.07)
1 232 (40.6) 63 (41.7) 37 (45.12) 26 (37.68)
2-3 48 (8.3) 11 (7.3) 6 (7.32) 5 (7.25)
White blood cells, median (range), 3109/L 10.5 (0.5-990) 16.8 (1.0-282.0) 13.3 (1.2-282.0) 20.8 (1.0-260.0) .3361
Hemoglobin, median (range), g/dL 9.1 (3-15.8) 9.2 (5.1-15.8) 9.5 (5.3-14.1) 8.8 (5.1-15.8) .5376
Platelets, median (range), 3109/L 53 (2-852) 51.0 (2.0-852.0) 53.0 (2.0-373.0) 46.0 (10.0-852.0) .2334
Diagnosis, n (%) .6510
De novo AML 494 (86.4) 140 (92.7) 75 (91.46) 65 (94.20)
Secondary (MPN/MDS) 49 (8.6) 9 (6.0) 5 (6.10) 4 (5.80)
Therapy related 29 (5.1) 2 (1.3) 2 (2.44) 0 (0.00)
Cytogenetics, n (%) .1748
SR 52 (9.1) 22 (14.6) 9 (10.98) 13 (18.84)
t(8,21) 20 (3.5) 10 (6.6) 6 (7.32) 4 (5.80)
Inv(16) 31 (5.4) 11 (7.3) 3 (3.66) 8 (11.59)
del(16) 1 (0.2) 1 (0.7) 0 (0.00) 1 (1.45)
Normal (46 XX/XY) 272 (47.6) 70 (46.4) 45 (54.88) 25 (36.23)
Intermediate risk 21 (3.7) 8 (5.3) 4 (4.88) 4 (5.80)
HR 170 (29.7) 42 (27.8) 21 (25.61) 21 (30.44)
Unknown 57 (10.0) 9 (6.0) 3 (3.66) 6 (8.70)
Genetics
RUNX1-RUNX1T1, n 558 144 75 69 .7481
Rearranged, n (%) 27 (4.8) 10 (6.9) 6 (8.0) 4 (5.8)
CBF-MYH11, n 557 144 75 69 .0221
Rearranged n (%) 41 (7.4) 14 (9.7) 3 (4.0) 11 (15.9)
NPM1, n 551 143 76 67 .1617
Mutant n (%) 167 (30.3) 47 (32.9) 28 (36.8) 19 (28.4)
FLT3-ITD, n 569 145 76 69 .7990
Mutant n (%) 103 (18.1) 35 (24.1) 19 (25.0) 16 (23.2)
MLL-PTD, n 397 119 68 51 .0445
Mutant n (%) 24 (6.0) 12 (10.1) 6 (8.8) 6 (11.8)
CEBPA, n 361 150 81 69 .0239
Mutant (double mutation) n (%) 19 (5.3) 8 (5.3) 1 (1.2) 7 (10.1)
NILG risk classification, n (%) .1048
SR 156 (27.3) 51 (33.8) 23 (28.0) 28 (40.6)
HR 416 (72.7) 100 (66.2) 59 (72.0) 41 (59.4)
ELN 2010 risk classification, n 518 144 80 64 .1688
Favorable, n (%) 166 (32.0) 56 (38.9) 27 (33.8) 29 (45.3)
Intermediate 1, n (%) 147 (28.4) 35 (24.3) 25 (31.2) 10 (15.6)
Intermediate 2, n (%) 70 (13.5) 18 (12.5) 9 (11.3) 9 (14.1)
Adverse, n (%) 135 (26.1) 35 (24.3) 19 (23.7) 16 (25.0)
PBC study patients represented 26.3% of all trial patients and expressed comparable clinico-biologic and risk features. Among PBC study patients, those randomized to HDS
chemotherapy were significantly younger than the control patients.
ECOG, Eastern Conference Oncology Group; ITD, internal tandem duplication.
*ICE vs HDS. Differences between treatment groups were evaluated using the Mann-Whitney U test for continuous variables and Pearson’s x2 test (or Fisher’s exact tests for cells ,10)
for categorical variables.
28 JANUARY 2020 x VOLUME 4, NUMBER 2 PERIPHERAL CLEARANCE IN ACUTE MYELOID LEUKEMIA 305
PBClow profile in CR patients was better assessed in DFS and CIR
graphs, with a significantly lower risk for relapse and higher DFS
rate in the PBChigh group. In subset analyses matching PBC results
with treatment arm, PBClow patients from the nonintensive ICE arm
had the worst outcome, whereas prognosis was improved without
significant differences for PBChigh patients in either induction arm
(Figure 4). In multivariate risk models, PBC and ELN or NILG risk
scores were the 2 independent factors retaining a significant
predictive power for DFS, EFS, CIR, and OS (supplemental File
S2.9). In the main clinical trial, we found a strong independent
correlation between survival and both HDS induction and allogeneic
stem cell transplantation (SCT)15; therefore, we compared SCT-
related effects in patients with PBChigh or PBClow CR using the
Mantel-Byar method and Simon-Makuch plots to correct for pre-SCT
events considering SCT as a time-dependent variable. In this analysis
of DFS and CIR, the outcome in PBChigh patients was further
improved by SCT (n5 32/86); however, the same was not observed
in PBClow patients (n 5 17/34). Repeating the same tests in HR
patients strictly eligible for SCT according to trial design, the results
were equally significant, with a greater efficacy of SCT in the PBChigh
group and a partial nonsignificant protection from relapse in the
PBClow group (supplemental File S2.10).
Discussion
For decades, “713” chemotherapy (cytarabine plus an anthracycline)
has remained the standard initial treatment for non-promyelocytic
AML. Indeed, with this regimen, ;70% of younger patients achieve
an initial CR.
Main clinical trials investigating intensified induction demonstrated
an increased CR rate after a single course but only showed a clear
benefit on survival in subgroups of patients.25-27
Given the heterogeneity of the disease, if applied uniformly, each 1
of these strategies turns out to be inappropriate. Current prognostic
stratification drives the therapeutic approach in the post-CR phase,
but it generally does not modulate the intensity of induction
treatment, particularly in the large heterogeneous category of
intermediate cytogenetics.28
The early identification of patients likely to present primary treatment
resistance would allow an early shift to more effective therapeutic
alternatives. To this end, several lines of evidence support using the
early kinetics of blast cell clearance from PB during induction
therapy.9-14 To develop a prospective clinical application using such
an approach, the 2 major issues of methodology and calculation
modality need to be addressed carefully. Among the 3 methods
used, morphology,9,10 MFC,11-14 and molecular genetics,29 mor-
phology is the least adequate because of its dependence on
operator and scarce standardization, particularly at later time points
as a result of worsening cytopenia. By analogy, the place of
modern automated cell counters in PBC analysis is yet to be
determined. Molecular genetics would offer the highest level of
standardization, but the need for genetic probes limits the
spectrum of its applicability and, above all, it is time consuming,
a major concern for a real-time PBC study. MFC offers the best
balance between method standardization and real-time informa-
tion, and a LAIP-based approach provides high specificity,
especially with low blast fraction or monocytic differentiation.
With regard to data interpretation, PBC was expressed as
time to disappearance/reduction of blasts11 or the normalized
ratio between baseline and a predefined time point.12-14 The
former approach is less suitable for a prospective multicenter
and therapy-oriented trial because the study parameter fluc-
tuates among patients, making study logistics challenging and
Table 2. Outcome to induction therapy after course 1 according to PBC response and randomization arm
All patients CR patients* NR patients ED patients P†
Patients, n (%) 151 (100.0) 108 (71.5) 34 (22.5) 9 (6.0)
LAIP1 cells/mL, median (range)
Day 1 4198.2 (120.4-148859.3) 4 502.2 (134.2-106933.8) 2 853.12 (120.4-148859.3) 1 496.8 (1 558-71 331.8) .24
Day 4 41.8 (0.1-44 802.3) 29.4 (0.1-11 035.5) 104.5 (0.2-44 802.3) 96.0 (1.8-627.8) .001
PBC (log reduction)
Median (range) 1.9 (0.3-4.5) 2.3 (0.4-4.3) 1.0 (0.3-4.5) 1.4 (0.5-2.9) ,.0001
PBChigh, n (%) 96 (63.6) 84 (77.8) 8 (23.5) 4 (44.4) ,.0001
PBClow, n (%) 55 (36.4) 24 (22.2) 26 (76.5) 5 (55.6)
PBC by randomization arm
ICE arm (n 5 82)
Median (range) 1.8 (0.3-4.5) 2.2 (0.4-4.0) 1.0 (0.3-4.5) 1.4 (0.5-2.9) ,.0001
PBChigh, n (%) 46 (56.1) 39 (78.0) 4 (16.0) 3 (14.3) ,.0001
PBClow, n (%) 36 (43.9) 11 (22.0) 21 (84.0) 4 (85.7)
HDS arm (n 5 69)
Median (range) 2 (0.6-4.2) 2.4 (0.6-4.2) 1.5 (0.7-2.5) 1.4 (1.0-1.9) .02
PBChigh, n (%) 50 (72.5) 45 (77.6) 4 (44.4) 1 (50.0) .05
PBClow, n (%) 19 (27.5) 13 (22.4) 5 (55.6) 1 (50.0)
P (HDS vs ICE arm) 0.04 0.72 0.08 0.89
*Number of CR patients in ICE arm (N 5 82) vs HDS arm (N 5 69): n 5 50 (61%) vs n 5 58 (84.1%) (P 5 .003).
†Mann-Whitney U test or Kruskal-Wallis test was used for continuous variables; Pearson’s x2 test was used for categorical variables.
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hampering the consistency of PBC assessment and possible
PBC-based interventions.
Using a normalized PBC ratio platform combining diagnostic
precision with ease of implementation, our study demonstrated
a strong positive correlation among a PBChigh response (.1.5 log
by ROC analysis), CR obtained after single-course chemotherapy,
and improved outcome with lower relapse risk and better survival.
The prognostically favorable PBC-related effect was largely in-
dependent of other risk factors and was confirmed by multivariate
statistical analysis. With regard to its predictive power, we
documented that 84 and 87 of 96 PBChigh patients achieved CR
at course 1 (87.5%) or later (90.6%), respectively. The proportions
increased to 91.3% and 94.5%, respectively, after the exclusion of
4 patients experiencing induction death during aplasia whose BM
was not examined for morphological CR. Thus, the predictive power
of the method for CR was close to 95% in fully evaluable patients,
with only 8 patients not exhibiting a relationship between PBChigh
status and CR. In these patients, we can argue that the selected
LAIP was not sufficiently representative of the dominant AML clone,
it changed rapidly toward a chemoresistant subclone, and/or there
were other unrecognized adverse characteristics (eg, marrow
fibrosis); alternatively, it might have reflected a fast kinetic relapse
after a transient good PBC response. In these 8 patients we
observed a high incidence of secondary disease (supplemental File
S2.11), which suggests the influence of a higher clonal heteroge-
neity in PBC assessment. Tracking leukemic stem cells may provide
further insight into actual disease chemosensitivity, as proposed
previously.30 In the future, dissecting the clonal heterogeneity of
AML with new mass cytometry techniques could improve the
sensitivity and predictive power of PBC and MRD studies for
clinical use.31 Moreover, in our study, the predictive role of CR in
Table 3. Univariate and multivariate analysis for achievement of CR at R1 evaluation
CR/N (%)
Univariate Multivariate*
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age, y
,60 77/95 (81.1) 3.45 (1.65-7.20) .001 2.55 (0.99-6.57) .05 2.37 (0.82-6.88) .11
$60 31/56 (55.4) 1.00 1.00 1.00
Sex
Male 53/78 (67.9) 1.00 1.00 1.00
Female 55/73 (75.3) 1.44 (0.71-2.94) .32 1.33 (0.54-3.27) .53 1.07 (0.40-2.82) .89
WBCs, 3109/L
#50 75/108 (69.4) 1.00 1.00
.50 33/43 (76.7) 1.45 (0.64-3.29) .37 1.18 (0.40-3.51) .77
AML
Secondary 4/11 (36.4) 1.00 1.00
De novo 104/140 (74.3) 5.06 (1.40-18.29) .01 3.25 (0.61-17.22) .17
ECOG performance status
0 62/77 (80.5) 3.44 (0.93-12.82) .07 1.61 (0.33-7.81) .55 1.77 (0.33-9.65) .51
1 40/63 (63.5) 1.45 (0.40-5.28) .57 1.20 (0.25-5.69) .82 1.25 (0.23-6.71) .79
2 6/11 (54.5) 1.00 1.00 1.00
NILG risk class
SR 46/51 (90.2) 5.64 (2.06-15.44) .0008 3.64 (1.17-11.35) .02
HR 62/100 (62.0) 1.00 1.00
ELN 2010 risk class†
Favorable 51/56 (91.1) 12.11 (3.90-37.65) ,.0001 5.90 (1.57-22.18) .008
Intermediate 1 24/35 (68.6) 2.59 (0.98-6.87) .05 1.41 (0.40-4.90) .59
Intermediate 2 11/18 (61.1) 1.87 (0.59-5.94) .29 1.03 (0.25-4.26) .97
Adverse 16/35 (45.7) 1.00 1.00
Treatment
ICE 50/82 (61.0) 1.00 1.00 1.00
sHD 58/69 (84.1) 3.38 (1.54-7.38) .002 2.27 (0.90-5.71) .08 2.38 (0.84-6.71) .10
PBC
,1.5 24/55 (43.6) 1.00 1.00 1.00
$1.5 84/96 (87.5) 9.04 (4.04-20.24) ,.0001 7.01 (2.91-16.91) ,.0001 5.87 (2.22-15.53) .0004
OR, odds ratio.
*Two multivariate models including different risk classifications (model with NILG risk excludes factors already considered in the risk construction).
†Evaluable patients 5 144.
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conjunction with a PBChigh profile was validated in all risk subsets
defined by genetics/cytogenetics (ELN classification), with different
PBC and CR rates reflecting the disease biology. The vast majority
(87%) of ELN favorable-risk patients belonged to the PBChigh
group, compared with less than half (44.4%) of the ELN adverse-risk
patients; the ELN intermediate-risk categories had intermediate PBC
behavior (67.3% and 48.1% of ELN intermediate-risk 1 and 2 cases
were PBChigh, respectively). The clinical correlation was signifi-
cant, because the CR rate decreased progressively across the 4
ELN risk categories.
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In contrast, the PBClow group exhibited a markedly lower probability
of CR (43.6%, P , .0001), especially with a PBC ,1.0 (CR 28%),
and much higher chemoresistance rates. Although the PBClow
profile was not as sensitive a predictor of resistance as PBChigh was
for CR, because nearly half of PBClow patients achieved CR,
PBClow CR patients had significantly shorter DFS with a higher
incidence of relapse. This suggests an interaction between PBClow
scores and higher risk stratification (as shown in ELN risk class
analysis) and higher residual leukemic burden compared with
PBChigh patients, despite morphological CR. Although a post-
induction MRD study was not performed in this trial, this correlation
was reported by other investigators, which suggests that combining
PBC and MRD data may lead to more precise identification of the
patients who are at the highest risk of failure within each AML risk
subset. Because a significant proportion of PBChigh patients also
relapsed, postinduction MRD analysis (with molecular probe or
LAIP sensitivity$1024; ie,$3 log) should be routinely performed to
more accurately define the risk category and to guide treatment
choices.32
Another main point of this study was the comparative PBC analysis
between the 2 chemotherapy arms of the randomized CR induction
trial. The PBC study patients were representative of the entire group
of trial patients and, as such, experienced a significantly higher CR
rate when allocated to the HDS arm.15 Upon assessing whether
the CR induction results correlated positively with PBC scores, we
found that median PBC values were significantly higher and that
more PBChigh patients were in CR after 1 course of HDS, rather
than ICE, chemotherapy (P 5 .04). This seemed to be related to a
more rapid and profound LAIP1 cell depletion induced by high-dose
cytarabine.
A weakness of this study was the lack of LAIP reassessment in BM
samples examined at the response evaluation and subsequent MRD
analysis. These tests were not planned in this study but should be
performed in future investigations. The exclusion of patients lacking
a suitable LAIP profile from the PBC study was unavoidable, as in
other studies, whereas the inclusion of only 31% of 574 total trial
patients did not preclude the collection of significant PBC-based
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clinico-prognostic data according to study arm and AML risk subset
among comparable patient series.
The PBC approach is simple and minimally invasive, providing an
absolute functional quantification of leukemic burden reduction that
is not affected by some variables (ie, overall cellularity, dilution by
PB) expected with BM assessment. It allows the early identification
of high-risk patients who would potentially benefit from intensifica-
tion, as demonstrated by the improved outcome provided by HDS
induction in the PBC-low subset.
We surmise that an early PBC analysis can contribute to a significant
improvement in risk classification, because PBClow patients are actually
moved to the high-risk class, thereby adding relevant information to
optimize induction therapy in the setting of intervention trials exploring
new agents and/or compare established therapeutic options.
This powerful and early prognostic indicator might allow personal-
ization of the therapeutic strategy for AML patients from the very
first days of the induction course. In this regard, we are in the
process of launching a multicenter trial (Eudract number 2019-
003936-21) within the Gruppo Italiano Malattie EMatologiche
dell’Adulto cooperative group, in which induction treatment is
largely based on results of PBC. In fact, as soon as PBC data
predict poor response during standard induction, the patient will be
switched to intensified induction with high-dose cytarabine with the
aim of increase the proportion of those reaching CR, as well as
reducing the toxicity associated with the greater number of courses
of treatment needed to achieve CR. Conversely, for patients in
whom PBC data predict a good response, standard induction
therapy is continued, thus avoiding the extra toxicity associated with
generalized upfront use of intensification. Because the therapeutic
scenario in AML is rapidly evolving, we believe that this model,
which is able to provide an early assessment of chemosensitivity,
might be useful to rationalize the introduction of novel targeted
agents that are emerging as effective treatment modalities.33-35
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